Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published
News Nov 25, 2010
Specifically the study, published by Horizon Discovery co-founder Professor Alberto Bardelli (Universityof Torino) and SAB member Professor Sabine Tejpar (University of Leuven), found that patients carrying a particular and relatively common (20% of mutant KRAS cases) form of mutant KRAS (the G13D variant) are not resistant to Erbitux therapy, as was previously assumed. These findings, confirmed in the in-vivo and clinical patient samples, suggest that more detailed analysis of specific mutant KRAS variants in prospective clinical trials are required to reveal the true impact of specific mutant KRAS variants on patients receiving Erbitux therapy.
A copy of the publication is available to view online.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019